| Literature DB >> 27305971 |
Kang Zhang1,2, Xuguo Duan1,2, Jing Wu1,2.
Abstract
Bacillus subtilis ATCC 6051a is an undomesticated strain used in the industrial production of enzymes. Because it is poorly transformable, genetic manipulation in this strain requires a highly efficient genome editing method. In this study, a Streptococcus pyogenes CRISPR/Cas9 system consisting of an all-in-one knockout plasmid containing a target-specific guide RNA, cas9, and a homologous repair template was established for highly efficient gene disruption in B. subtilis ATCC 6051a. With an efficiency of 33% to 53%, this system was used to disrupt the srfC, spoIIAC, nprE, aprE and amyE genes of B. subtilis ATCC 6051a, which hamper its use in industrial fermentation. Compared with B. subtilis ATCC 6051a, the final mutant, BS5 (ΔsrfC, ΔspoIIAC, ΔnprE, ΔaprE, ΔamyE), produces much less foam during fermentation, displays greater resistant to spore formation, and secretes 2.5-fold more β-cyclodextrin glycosyltransferase into the fermentation medium. Thus, the CRISPR/Cas9 system proved to be a powerful tool for targeted genome editing in an industrially relevant, poorly transformable strain.Entities:
Mesh:
Year: 2016 PMID: 27305971 PMCID: PMC4910044 DOI: 10.1038/srep27943
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1CRISPR/Cas9 system plasmids, homologous repair template and editing procedure.
(a) Relevant features of pHY300PLK-β-CGTase and the knockout plasmids. p15A ori, E. coli replication origin; repB, B. subtilis replication origin; PE194, B. subtilis temperature-sensitive replication origin; AmpR, ampicillin-resistance marker; TcR, tetracycline resistance marker; PamyR, promoter of ampicillin-resistance marker; PamyQ, α-amylase promoter from B. amyloliquefaciens; β-CGTase, β-CGTase encoding gene; cas9, Cas9 encoding gene; sgRNA, target-specific guide RNA; N20, 20-bp complementary region; repair template, homologous repair template obtained by overlap PCR. (b) Diagram showing the design of a 934 bp repair template for the specific target within srfC. The 6 bp deletion includes 1 bp of the PAM and the last 5 bp of the guide sequence. The 11 bp insertion includes an Xho I restriction site and 5 bp of random sequence. (c) Detailed diagram of CRISPR/Cas9 system mediated continual genome editing in B. subtilis ATCC 6051a.
Figure 2The foam height and cell growth of B. subtilis ATCC 6051a and BS1 in 3 L fermenter.
During the fermentation, the foam height of B. subtilis ATCC 6051a (Δ) and BS1 (▲), and the dry cell weight (DCW) of B. subtilis ATCC 6051a (□) and BS1 (■) was measured. The antifoam was added to B. subtilis ATCC 6051a (dotted arrow) and BS1 (solid arrow) when foam height reach the limit.
Figure 3Confirmation of the srfC disruption, spoIIAC disruption, nprE disruption, aprE disruption and amyE disruption.
Digesting the PCR product of upstream and downstream regions with Xho I. The digestion products were analysed by agarose gel electrophoresis. Lane M: DNA marker; lane WT: digestion of overlap PCR product using B. subtilis ATCC 6051a genomic DNA as the template; lane MT: digestion of overlap PCR product using the indicated gene disruption mutant genomic DNA as the template.
Figure 4Detection of protease activity and α-amylase activity.
(a) Transparent rings formed on 5% non-fat powdered milk medium to detect the protease activity of mutants BS2, BS3 and BS4; (b) The mutants BS4 and BS5 were grown on LB plate containing 1% soluble starch, then the colonies were wiped; and (c) the plate was stained with iodine.
Figure 5Enzyme assay of β-CGTase expression in B. subtilis ATCC 6051a and BS5.
During the fermentation, β-CGTase activity of B. subtilis ATCC 6051a (□) and BS5 (■), and DCW of B. subtilis ATCC 6051a (Δ) and BS5 (▲) was measured.
Time required for Bacillus subtilis genome editing by the current existing methods.
| Delivery plasmid | Counter-selectable marker | Cre/loxP | CRISPR/Cas9 |
|---|---|---|---|
| Plasmid construction (8 days | Plasmid construction8 days | Plasmid construction (8 days) | Plasmid construction (9 days) |
| Transformation (1.5 days) | Transformation (1.5 days) | The PCR fusion of | Transformation (1.5 days) |
| Marker deletion (3 days) | Counter-selectable marker integration by single cross-over (3 days) | PCR product transformation (1.5 days) | Verification and plasmid curing (2 days) |
| Verification (1.5 days) | Counter-selectable marker eviction by double cross-over (2 days) | pTSC plasmid transformation and recombination mediated by cre recombinase (1.5 days) | |
| Verification (1.5 days) | Verification and plasmid curing (2 days) | ||
| Total 14 days | Total 16 days | Total 14 days | Total 12.5 days |
*The time in the table was calculated in the least time required for each manipulation.
Strains and plasmids used in this study.
| Strain or plasmid | characteristics | reference |
|---|---|---|
| Strains | ||
| Takara | ||
| Wild type | ATCC | |
| BS1 | ATCC 6051a derivative, Δ | This work |
| BS2 | ATCC 6051a derivative, Δ | This work |
| BS3 | ATCC 6051a derivative, Δ | This work |
| BS4 | ATCC 6051a derivative, Δ | This work |
| BS5 | ATCC 6051a derivative, Δ | This work |
| Plasmids | ||
| pMD18-T | Ampr, MCS | Takara |
| pHY300PLK | Ampr ( | Takara |
| pHY300PLK-β-CGTase | Ampr ( | This lab |
| pwtCas9-bacteria | Ampr, tetracycline repressor TetR, | Stanley Qi |
| pHYcas9d | Ampr ( | This work |
| pHYcas9dsrf1 | Ampr ( | This work |
| pHYcas9dsrf2 | pHYcas9dsrf1 derivative with repair template for 284 bp deletion of | This work |
| pHYcas9dspo | pHYcas9dsrf derivative with sgRNA and repair template of | This work |
| pHYcas9dnpr | pHYcas9dsrpf derivative with sgRNA and repair template of | This work |
| pHYcas9dapr | pHYcas9dsrf derivative with sgRNA and repair template of | This work |
| pHYcas9damy | pHYcas9dsrf derivative with sgRNA and repair template of | This work |
Primers used in this study.
| primers | Sequence (5′−3′) |
|---|---|
| P01 | TTTCTTATACAAATTATATTTTACATATCAAT |
| P02 | GGCAACCGTAAGCTTGGTAAT |
| P03 | AATTTGTATAAGAAAATGGATAAGAAATACTCAATAGGCT |
| P04 | AAGCTTACGGTTGCCTTAGTCACCTCCTAGCTGACTC |
| P05 | GCGTCTGTACGTTCCTTAAGG |
| P06 | GTAGTTCAACAAACGGGCC |
| P07 | GGAACGTACAGACGCATTTTACATTTTTAGAAATGGGC |
| P08 | CGTTTGTTGAACTACGCAGTCGGCTTAAACCAG |
| P09 | C |
| P10 | GCTGCCCCTAGCCTCGAGTGTGTCAGATCGATTTCTTC |
| P11 | CTCGAGGCTAGGGGCAGCGAGCAAACAGC |
| P12 | C |
| P13 | C |
| P14 | CTTTTGTTCGCGCAGAGTCGTGAATGAACACGGTACG |
| P15 | CCGTGTTCATTCACGACTCTGCGCGAACAAAAGCC |
| P16 | C |
| P17 | TTGTTTGGTCTGTCGTACAGGTTTTAGAGCTAGAAATAGCAAGTTAA |
| P18 | CTGTACGACAGACCAAACAATTATATTTTACATAATCGCGCGC |
| P19 | C |
| P20 | AAAAACCCTGGCCTCGAGCGACAGACCAAACAAGACGC |
| P21 | CTCGAGGCCAGGGTTTTTAAACAGAGGATATGAGC |
| P22 | C |
| P23 | GCACTCGCTTTCAAAGCTATGTTTTAGAGCTAGAAATAGCAAGTTAA |
| P24 | ATAGCTTTGAAAGCGAGTGCTTATATTTTACATAATCGCGCGC |
| P25 | C |
| P26 | ATTTGCCTCGATCTCGAGTTTGAAAGCGAGTGCCAGC |
| P27 | CTCGAGATCGAGGCAAATCACCAGACGCTGT |
| P28 | C |
| P29 | CCTGACTTAAACGTCAGAGGGTTTTAGAGCTAGAAATAGCAAGTTAA |
| P30 | CCTCTGACGTTTAAGTCAGGTTATATTTTACATAATCGCGCGC |
| P31 | C |
| P32 | TTGCTCCGGCGTCTCGAGGACGTTTAAGTCAGGATGAGAAG |
| P33 | CTCGAGACGCCGGAGCAAGCTTCGTACCTTC |
| P34 | C |
| P35 | GTCACGCAGAATTCATTGCTGTTTTAGAGCTAGAAATAGCAAGTTAA |
| P36 | AGCAATGAATTCTGCGTGACTTATATTTTACATAATCGCGCGC |
| P37 | C |
| P38 | ACAGCCCGGAACCTCGAGTGAATTCTGCGTGACATCCC |
| P39 | CTCGAGGTTCCGGGCTGTATGACTGGAATACAC |
| P40 | C |
*The restriction enzyme sites are bold and underlined.